Original Article :   Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12/23 inhibitors, and interleukin 23 inhibitors: An emulated target trial analysis What are the key takeaways of this article? Psoriasis and psoriatic arthritis, collectively referred to as psoriatic disease, are chronic inflammatory conditions that not only affect...

Original Article : A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis What...